×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ATOS – atossa therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ATOS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/5
08:30 am
atos
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
Medium
Report
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
1/23
05:06 am
atos
Atossa Genetics (NASDAQ:ATOS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Atossa Genetics (NASDAQ:ATOS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
1/21
09:28 am
atos
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 [Yahoo! Finance]
Low
Report
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 [Yahoo! Finance]
1/21
09:05 am
atos
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
Low
Report
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
1/16
05:28 pm
atos
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy [Yahoo! Finance]
High
Report
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy [Yahoo! Finance]
1/16
04:40 pm
atos
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
Medium
Report
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
1/16
06:47 am
atos
Atossa Therapeutics shares rise after FDA grants orphan drug designation for soft tissue sarcoma [Seeking Alpha]
Low
Report
Atossa Therapeutics shares rise after FDA grants orphan drug designation for soft tissue sarcoma [Seeking Alpha]
1/6
08:37 am
atos
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer [Yahoo! Finance]
Medium
Report
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/30
08:30 am
atos
Form 4/A ATOSSA THERAPEUTICS, For: Jan 20 Filed by: QUAY STEVEN C
Medium
Report
Form 4/A ATOSSA THERAPEUTICS, For: Jan 20 Filed by: QUAY STEVEN C
1/26
08:00 am
atos
Form 8-K ATOSSA THERAPEUTICS, For: Jan 20
Medium
Report
Form 8-K ATOSSA THERAPEUTICS, For: Jan 20
1/22
02:12 pm
atos
Form 4 ATOSSA THERAPEUTICS, For: Jan 20 Filed by: QUAY STEVEN C
Low
Report
Form 4 ATOSSA THERAPEUTICS, For: Jan 20 Filed by: QUAY STEVEN C
1/9
08:16 am
atos
Form 8-K ATOSSA THERAPEUTICS, For: Jan 09
Medium
Report
Form 8-K ATOSSA THERAPEUTICS, For: Jan 09
1/6
08:30 am
atos
Form 8-K ATOSSA THERAPEUTICS, For: Jan 06
Low
Report
Form 8-K ATOSSA THERAPEUTICS, For: Jan 06
12/22
08:30 am
atos
Form DEF 14A ATOSSA THERAPEUTICS, For: Dec 19
Medium
Report
Form DEF 14A ATOSSA THERAPEUTICS, For: Dec 19
12/12
05:01 pm
atos
Form PRE 14A ATOSSA THERAPEUTICS, For: Dec 12
High
Report
Form PRE 14A ATOSSA THERAPEUTICS, For: Dec 12
12/4
08:15 am
atos
Form 8-K ATOSSA THERAPEUTICS, For: Dec 04
Low
Report
Form 8-K ATOSSA THERAPEUTICS, For: Dec 04
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/27
Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density
22.9%
3/30 New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients 10.3%
4/17 COVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predicted 9.0%
10/16 Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology 7.6%
3/13 Atossa to meet with FDA on Endoxifen development [Seeking Alpha] 7.1%
5/21 Form 4 ATOSSA GENETICS INC For: May 17 Filed by: Steinhart Richard I 5.9%
3/26 Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update 4.8%
5/30 Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019 4.0%
4/13 Form 4 ATOSSA THERAPEUTICS, For: Apr 09 Filed by: Guse Kyle 3.4%
12/18 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. 2.5%
3/30 New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients 10.3%
4/17 COVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predicted 9.0%
10/16 Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology 7.6%
3/13 Atossa to meet with FDA on Endoxifen development [Seeking Alpha] 7.1%
5/21 Form 4 ATOSSA GENETICS INC For: May 17 Filed by: Steinhart Richard I 5.9%
3/26 Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update 4.8%
5/30 Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019 4.0%
4/13 Form 4 ATOSSA THERAPEUTICS, For: Apr 09 Filed by: Guse Kyle 3.4%
12/18 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. 2.5%
TOP News Decliners
4/16
Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program
-26.0%
7/11 Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated -24.8%
4/27 Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study -21.9%
4/20 Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study -17.0%
5/13 Form 8-K ATOSSA GENETICS INC For: May 13 -10.6%
12/19 Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women -8.4%
4/2 Atossa Therapeutics Announces Clinical Progress -7.8%
6/27 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -4.9%
11/13 Form 10-Q ATOSSA GENETICS INC For: Sep 30 -4.7%
8/13 Q2/2019 6/30/2019 EPS -0.800 ZacksConsensus N/A ActVsEst N/A - N/A -4.5%
7/11 Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated -24.8%
4/27 Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study -21.9%
4/20 Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study -17.0%
5/13 Form 8-K ATOSSA GENETICS INC For: May 13 -10.6%
12/19 Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women -8.4%
4/2 Atossa Therapeutics Announces Clinical Progress -7.8%
6/27 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -4.9%
11/13 Form 10-Q ATOSSA GENETICS INC For: Sep 30 -4.7%
8/13 Q2/2019 6/30/2019 EPS -0.800 ZacksConsensus N/A ActVsEst N/A - N/A -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: